Astellas Pharma Inc. (“Astellas Pharma”; Headquarters: Chuo-ku, Tokyo; President and CEO: Yoshihiko Hatanaka) and sanofi-aventis K.K. (“sanofi-aventis”; Headquarters: Shinjuku-ku, Tokyo; Representative Director and President: Jez Moulding) announced that Astellas Pharma will transfer the rights to distribute the injectable antibiotics Targocid® (generic name: teicoplanin) and the treatment for peptic ulcer and gastritis Maalox® (generic name: dried aluminum hydroxide gel and magnesium hydroxide) to sanofi-aventis effective on January 1, 2012. This transfer of distribution rights is taking place based on the expiration of the contract.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,506 JPY | +3.51% | +1.72% | -10.68% |
Apr. 25 | Transcript : Astellas Pharma Inc., 2024 Earnings Call, Apr 25, 2024 | |
Apr. 25 | Astellas Pharma Inc. Announces Board and Committee Retirements | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.68% | 17.15B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- 4503 Stock
- News Astellas Pharma Inc.
- Astellas Pharma : Transfer of Distribution Rights for Targocid® and Maalox®